ZBIO PE Ratio & Valuation,Is ZBIO Overvalued

ZBIO Relative Valuation

ZBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZBIO is overvalued; if below, it's undervalued.

Historical Valuation

Zenas Biopharma Inc (ZBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 34.40 is considered Fairly compared with the five-year average of -4.03. The fair price of Zenas Biopharma Inc (ZBIO) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：40.59

Fair

-11.70

-8.49

EV/EBITDA

Zenas Biopharma Inc. (ZBIO) has a current EV/EBITDA of -8.49. The 5-year average EV/EBITDA is -1.94. The thresholds are as follows: Strongly Undervalued below -7.29, Undervalued between -7.29 and -4.62, Fairly Valued between 0.73 and -4.62, Overvalued between 0.73 and 3.41, and Strongly Overvalued above 3.41. The current Forward EV/EBITDA of -8.49 falls within the Strongly Undervalued range.

-9.58

EV/EBIT

Zenas Biopharma Inc. (ZBIO) has a current EV/EBIT of -9.58. The 5-year average EV/EBIT is -2.12. The thresholds are as follows: Strongly Undervalued below -7.88, Undervalued between -7.88 and -5.00, Fairly Valued between 0.77 and -5.00, Overvalued between 0.77 and 3.65, and Strongly Overvalued above 3.65. The current Forward EV/EBIT of -9.58 falls within the Strongly Undervalued range.

34.40

Zenas Biopharma Inc. (ZBIO) has a current PS of 34.40. The 5-year average PS is 33.63. The thresholds are as follows: Strongly Undervalued below -50.17, Undervalued between -50.17 and -8.27, Fairly Valued between 75.53 and -8.27, Overvalued between 75.53 and 117.43, and Strongly Overvalued above 117.43. The current Forward PS of 34.40 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Zenas Biopharma Inc. (ZBIO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.15. The thresholds are as follows: Strongly Undervalued below -5.21, Undervalued between -5.21 and -3.68, Fairly Valued between -0.62 and -3.68, Overvalued between -0.62 and 0.91, and Strongly Overvalued above 0.91. The current Forward P/OCF of 0.00 falls within the Overvalued range.

-11.59

P/FCF

Zenas Biopharma Inc. (ZBIO) has a current P/FCF of -11.59. The 5-year average P/FCF is -3.73. The thresholds are as follows: Strongly Undervalued below -9.23, Undervalued between -9.23 and -6.48, Fairly Valued between -0.99 and -6.48, Overvalued between -0.99 and 1.76, and Strongly Overvalued above 1.76. The current Forward P/FCF of -11.59 falls within the Strongly Undervalued range.

Zenas Biopharma Inc (ZBIO) has a current Price-to-Book (P/B) ratio of 8.74. Compared to its 3-year average P/B ratio of 2.40 , the current P/B ratio is approximately 263.93% higher. Relative to its 5-year average P/B ratio of 2.40, the current P/B ratio is about 263.93% higher. Zenas Biopharma Inc (ZBIO) has a Forward Free Cash Flow (FCF) yield of approximately -7.28%. Compared to its 3-year average FCF yield of -22.53%, the current FCF yield is approximately -67.70% lower. Relative to its 5-year average FCF yield of -22.53% , the current FCF yield is about -67.70% lower.

8.74

P/B

Median3y

2.40

Median5y

2.40

-7.28

FCF Yield

Median3y

-22.53

Median5y

-22.53

Competitors Valuation Multiple

The average P/S ratio for ZBIO's competitors is 21.82, providing a benchmark for relative valuation. Zenas Biopharma Inc Corp (ZBIO) exhibits a P/S ratio of 34.40, which is 57.66% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ZBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ZBIO in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Zenas Biopharma Inc (ZBIO) currently overvalued or undervalued?

What is Zenas Biopharma Inc (ZBIO) fair value?

ZBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Zenas Biopharma Inc (ZBIO) is between to according to relative valuation methord.

How does ZBIO's valuation metrics compare to the industry average?

What is the current P/B ratio for Zenas Biopharma Inc (ZBIO) as of Dec 15 2025?

As of Dec 15 2025, Zenas Biopharma Inc (ZBIO) has a P/B ratio of 8.74. This indicates that the market values ZBIO at 8.74 times its book value.

What is the current FCF Yield for Zenas Biopharma Inc (ZBIO) as of Dec 15 2025?

As of Dec 15 2025, Zenas Biopharma Inc (ZBIO) has a FCF Yield of -7.28%. This means that for every dollar of Zenas Biopharma Inc’s market capitalization, the company generates -7.28 cents in free cash flow.

What is the current Forward P/E ratio for Zenas Biopharma Inc (ZBIO) as of Dec 15 2025?

As of Dec 15 2025, Zenas Biopharma Inc (ZBIO) has a Forward P/E ratio of -11.70. This means the market is willing to pay $-11.70 for every dollar of Zenas Biopharma Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Zenas Biopharma Inc (ZBIO) as of Dec 15 2025?

As of Dec 15 2025, Zenas Biopharma Inc (ZBIO) has a Forward P/S ratio of 34.40. This means the market is valuing ZBIO at $34.40 for every dollar of expected revenue over the next 12 months.

ZBIO Valuation